ArticleJournal of biomedical science
Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients.
Article in Journal of biomedical science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 66 citations in OpenAlex.
- Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon.PloS one · 2024Article
- Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection.Iranian journal of microbiology · 2023Article
- Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview.Clinical and experimental medicine · 2023Review
- Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses.Archives of medical research · 2022Article
- Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Role of the humoral immune response during COVID-19: guilty or not guilty?Mucosal immunology · 2022Review
- Screening and identification of B cell epitope of the nucleocapsid protein in SARS-CoV-2 using the monoclonal antibodies.Applied microbiology and biotechnology · 2022Article
- Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.Vaccine · 2022Article
- The striking mimics between COVID-19 and malaria: A review.Frontiers in immunology · 2022Review
- Recent advances in immunoassay technologies for the detection of human coronavirus infections.Frontiers in cellular and infection microbiology · 2022Review
- Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review.Bioengineered · 2021Review
- Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses.Nature communications · 2021Article
- Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.Bioscience reports · 2021Article
- SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.Journal of medical virology · 2021Article
- The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.Archives of virology · 2021Review
- Article
- Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.Clinical immunology (Orlando, Fla.) · 2021Review
- COVID-19 vaccine: where are we now and where should we go?Expert review of vaccines · 2021Review
- Recent advances in vaccine and immunotherapy for COVID-19.Human vaccines & immunotherapeutics · 2020Review
- Establishing a high sensitivity detection method for SARS-CoV-2 IgM/IgG and developing a clinical application of this method.Emerging microbes & infections · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome (SARS), a new disease with symptoms similar to those of atypical pneumonia, raised a global alert in March 2003. Because of its relatively high transmissibility and mortality upon infection, probable SARS patients were quarantined and treated with special and intensive care. Therefore, instant and accurate laboratory confirmation of SARS-associated coronavirus (SARS-CoV) infection has become a worldwide interest. For this need, we purified recombinant proteins including the nucleocapsid (N), envelope (E), membrane (M), and truncated forms of the spike protein (S1-S7) of SARS-CoV in Escherichia coli. The six proteins N, E, M, S2, S5, and S6 were used for Western blotting (WB) to detect various immunoglobulin classes in 90 serum samples from 54 probable SARS patients. The results indicated that N was recognized in most of the sera. In some cases, S6 could be recognized as early as 2 or 3 days after illness onset, while S5 was recognized at a later stage. Furthermore, the result of recombinant-protein-based WB showed a 90% agreement with that of the whole-virus-based immunofluorescence assay. Combining WB with existing RT-PCR, the laboratory confirmation for SARS-CoV infection was greatly enhanced by 24.1%, from 48.1% (RT-PCR alone) to 72.2%. Finally, our results show that IgA antibodies against SARS-CoV can be detected within 1 week after illness onset in a few SARS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.